Search results for "Chronic Kidney Disease"
showing 10 items of 119 documents
The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.
2015
Background Cardiovascular disease (CVD) risk is substantially increased in subjects with chronic kidney disease (CKD). The Triglycerides (TG) to High-Density Lipoprotein Cholesterol (HDL-C) ratio is an indirect measure of insulin resistance and an independent predictor of cardiovascular risk. No study to date has been performed to evaluate whether the TG/HDL-C ratio predicts CVD risk in patients with CKD. Methods A total of 197 patients (age 53 ± 12 years) with CKD Stages 1 to 5, were enrolled in this longitudinal, observational, retrospective study. TG/HDL-C ratio, HOMA-IR indexes, serum asymmetric dimethyl arginine (ADMA), high sensitivity C-reactive protein (CRP), parathyroid hormone (PT…
Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review.
2010
Introduction Cardiovascular diseases are highly prevalent in patients with chronic kidney disease (CKD), and represent the major hazard for mortality in this population. Anomalies of left ventricular (LV) structure and function are very frequent too among CKD patients, and show a negative impact on cardiovascular prognosis. Methods We searched PubMed for manuscripts regarding left ventricular hypertrophy (LVH) in CKD. Definition of LVH was different according to different studies. Results In patients with end-stage renal disease, the prevalence of LVH is higher than 70%. Studies in patients with less advanced CKD have reported increasing prevalence of LVH along with declining renal function…
Coronavirus disease 2019 in chronic kidney disease
2020
Abstract The clinical spectrum of coronavirus disease 2019 (COVID-19) infection ranges from asymptomatic infection to severe pneumonia with respiratory failure and even death. More severe cases with higher mortality have been reported in older patients and in those with chronic illness such as hypertension, diabetes or cardiovascular diseases. In this regard, patients with chronic kidney disease (CKD) have a higher rate of all-type infections and cardiovascular disease than the general population. A markedly altered immune system and immunosuppressed state may predispose CKD patients to infectious complications. Likewise, they have a state of chronic systemic inflammation that may increase …
Is kidney a new organ target in patients with obstructive sleep apnea? Research priorities in a rapidly evolving field.
2021
Abstract The bidirectional relationship between sleep disordered breathing and chronic kidney disease (CKD) has recently gained a lot of interest. Several lines of evidence suggest the high prevalence of coexistent obstructive sleep apnea (OSA) in patients with CKD and end-stage renal disease (ESRD). In addition, OSA seems to result in loss of kidney function in some patients, especially in those with cardio-metabolic comorbidities. Treatment of CKD/ESRD and OSA can alter the natural history of each other; still better phenotyping with selection of appropriate treatment approaches is urgently needed. The aim of this narrative review is to provide an update of recent studies on epidemiologic…
Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C
2021
Publisher Copyright: © 2021 Kaartinen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Chronic kidney disease (CKD) is one of the most well-known extrahepatic manifestations caused by hepatitis C infection (HCV). CKD is typically discovered at a late stage. HCVnephropathy may show different histopathologic patterns, as both glomerular and tubulointerstitial damage have been described. Identification of patients with early renal manifestations would be beneficial to provide treatment and avoid progres…
GLP-1 Receptor agonists and diabetic kidney disease: A call of attention to nephrologists
2020
Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 r…
Cukrzyca typu 2 i przewlekła choroba nerek jako czynniki rokownicze w ostrym zapaleniu trzustki
2019
Przeprowadzono analizę czynników rokowniczych ostrego zapalenia trzustki (OZT). Dokonano krytycznego przeglądu najważniejszych skali rokowniczych OZT: Apache II, Ransona, BISAP, Sofa, Marshalla. Wskazano na ich ograniczenia, ale i przydatność kliniczną we wczesnej stratyfikacji prognostycznej OZT. W diagnostyce różnicowej należy wyodrębniać etiologię alkoholową i żółciopochodną. Występująca przed zachorowaniem cukrzyca typu 2 i przewlekła choroba nerek znamiennie pogarszają przebieg OZT i powinny być włączone do skali rokowniczych. Wykazano, że obecność cukrzycy z poziomem HBA1C powyżej 6,5% wiąże się ze zwiększoną śmiertelnością wśród chorych na OZT i wydłuża się okres hospitalizacji o 5 d…
Dzīves kvalitāte hroniskiem hemodialīzes pacientiem
2015
Bakalaura darba tēma: „Dzīves kvalitāte hroniskiem hemodialīzes pacientiem”. Mērķis: noskaidrot dzīves kvalitāti hroniskiem hemodialīzes pacientiem. Pētījuma jautājumi: 1. Kāda ir fiziskās dzīves kvalitāte hroniskiem hemodialīzes pacientiem?; 2. Kāda ir dzīves kvalitāte emocionālajā sfērā hroniskiem hemodialīzes pacientiem?; 3. Kāda ir dzīves kvalitāte neatkarības ziľā hroniskiem hemodialīzes pacientiem?; 4. Kāda ir sociālās dzīves kvalitāte hroniskiem hemodialīzes pacientiem? Bakalaura darbs sastāv no teorētiskās, pētnieciskās daļas un 5 pielikumiem. Darba teorētiskajā daļā analizēta M.E. Levainas Saglabāšanas teorija saistībā ar hronisku dialīzes pacientu aprūpi, apskatīta informācija par…
Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review
2021
Atrial fibrillation (AF) is the most common arrhythmia in chronic kidney disease (CKD), with a close bidirectional relationship between the two entities. The presence of CKD in AF increases the risk of thromboembolic events, mortality and bleeding. Vitamin K antagonists (VKA) have been the mainstay of treatment for the prevention of thromboembolic events in AF until recently, with confirmed benefits in AF patients with stage 3 CKD. However, the risk-benefit profile of VKA in patients with AF and stages 4–5 CKD is controversial due to the lack of evidence from randomized controlled trials. Treatment with VKA in CKD patients has been associated with conditions such as poorer anticoagulation q…
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease
2019
Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P) in patients with chronic HCV genotype 1-6 infections and compensated liver disease, including patients with chronic kidney disease stages 4 or 5 (CKD 4/5). Methods: Data from 9 Phase II and III clinical trials, assessing the efficacy and safety of G/P treatment for 8-16 weeks, were included. The presence of cirrhosis was determined at screening using a liver …